Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective standard treatment of non-small cell lung carcinoma (NSCLC). Here, we report a novel strategy to improve the efficacy of CDDP. In conditions in which CDDP alone or either of two PARP inhibi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Michels, Judith, Vitale, Ilio, Senovilla, Laura, Enot, David P., Garcia, Pauline, Lissa, Delphine, Olaussen, Ken A., Brenner, Catherine, Soria, Jean-Charles, Castedo, Maria, Kroemer, Guido
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Extra Views
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637345/
https://ncbi.nlm.nih.gov/pubmed/23428903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.24034
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars